Guardant Health, Inc.

Guardant Health, Inc. (often referred to as Guardant Health) is a publicly traded American biotechnology company headquartered in Palo Alto, California, with major operations also in Redwood City, California. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, it trades on Nasdaq under the ticker symbol GH. As of 2025, the company had approximately 2,506 employees. Guardant Health reported a trailing 12-month revenue of $1.08 billion as of March 31, 2026, and a market capitalization of $15.2 billion as of May 20, 2026.

Guardant Health specializes in precision oncology, developing and commercializing liquid biopsy tests to detect, monitor, and understand cancer through blood samples. Key product lines include the Guardant360® portfolio (Guardant360®, Guardant360® CDx, Guardant360® TissueNext®, Guardant360 Response™, GuardantINFINITY™) for advanced-stage cancer patients, and Guardant Reveal® for early-stage cancer patients. They also offer Shield™, an FDA-approved blood test for colorectal cancer screening. These tests analyze circulating tumor DNA (ctDNA) to inform treatment decisions, monitor for recurrence, and facilitate early cancer detection. Additionally, Guardant Health provides research and development services, including regulatory approval consultancy and clinical trial referrals.

Guardant Health operates as an active litigant in patent disputes, appearing as a defendant in four tracked cases and as a plaintiff in one, indicating a posture of both defending its intellectual property and asserting its rights. All cases are within U.S. federal jurisdictions, specifically the U.S. District Court for the District of Delaware and the Patent Trial and Appeal Board (PTAB).

Notable cases include Guardant Health, Inc. v. Tempus AI, Inc., where Guardant Health is a plaintiff, and a corresponding defendant case, Tempus AI Inc. v. Guardant Health Inc. at the PTAB, highlighting a two-way dispute between the two companies. Guardant Health has also been a defendant in patent challenges from Twinstrand Biosciences Inc. and Illumina, Inc., as well as a petitioner associated with Unified Patents at the PTAB, typically involving challenges to patent validity.